Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690 is registered in ClinicalTrials.gov with Aura Biosciences as lead sponsor.

NCT NCT06007690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06007690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Lead sponsor
Aura Biosciences
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 6, 2023
Completion date
August 15, 2028
Enrollment
108 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

choroidal melanoma, indeterminate lesions, ocular melanoma, uveal melanoma